Clinical Trials Sponsored by Transcept Pharmaceuticals

Total 19547 results

Processa Pharmaceuticals

Completed

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis (MOMENTUM)

Gastroparesis

United States
Azevan Pharmaceuticals

Completed

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)

Intermittent Explosive Disorder

United States
Vanda Pharmaceuticals

Completed

Relapse Prevention Study in Patients With Schizophrenia (REPRIEVE)

Schizophrenia

United States, India, Ukraine
Santhera Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (IONIA)

Friedreich's Ataxia

United States
CStone Pharmaceuticals

Active, not recruiting

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Spain, China, United States, Poland, Italy, Taiwan
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease
Vanda Pharmaceuticals

Completed

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Schizophrenia

United States
Regeneron Pharmaceuticals

Available

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Multiple Myeloma
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Allena Pharmaceuticals

Terminated

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Chronic Kidney Diseases | Hyperuricemia | Gout

United States
Dizal Pharmaceuticals

Completed

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Healthy Subjects

United States
BioCryst Pharmaceuticals

Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

Hereditary Angioedema | Prophylaxis | HAE

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Switzerland, United Kingdom, United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Serbia, Slovakia, South Africa, Spain
Regeneron Pharmaceuticals

Terminated

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE)

Familial Chylomicronemia

Korea, Republic of, Canada, Australia, Singapore, Belgium, Spain, Japan, United States, Austria, Germany, Ireland, Oman, Poland, Israel, New Zealand, Argentina, France, Croatia, Mexico, Serbia, Turkey
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine
Marinus Pharmaceuticals

Completed

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Infantile Spasms

United States
Cornerstone Pharmaceuticals

Completed

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Sarcoma, Clear Cell

United States
Lexicon Pharmaceuticals

Completed

Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1)

Diabetes | Diabetic Peripheral Neuropathy

United States
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States, Spain
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Glioblastoma

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

Multiple Sclerosis | Spasticity

United Kingdom
Titan Pharmaceuticals

Terminated

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Parkinson Disease

United States
Jazz Pharmaceuticals

Completed

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

Multiple Sclerosis

United Kingdom
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
BioCryst Pharmaceuticals

Active, not recruiting

A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

United Kingdom, Austria, South Africa
Santhera Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS)

Leber's Hereditary Optic Neuropathy (LHON)

United States, United Kingdom, Spain, Poland, Austria, Belgium, Bulgaria, Germany, Italy, Portugal
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
Jazz Pharmaceuticals

Completed

Sativex Thorough QT/QTc Study

Effects of Sativex on ECG

Canada
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Marinus Pharmaceuticals

Completed

Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) (TSC)

Tuberous Sclerosis

United States
Intercept Pharmaceuticals

Terminated

Obeticholic Acid in Pediatric Subjects With Biliary Atresia (CARE)

Biliary Atresia

Israel, United Kingdom, Poland, Belgium, France, Germany, Italy, Netherlands, Spain
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Regeneron Pharmaceuticals

Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Severe Hypertriglyceridemia (sHTG)

United States, Canada, Italy, United Kingdom
Ferring Pharmaceuticals

Completed

FIRMAGON Intensive Drug Monitoring Protocol

Prostate Cancer

China
Dizal Pharmaceuticals

Active, not recruiting

DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation

Non-Small Cell Lung Cancer

China
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
Endo Pharmaceuticals

Completed

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

Laxity; Skin | Cellulite | Edematous Fibrosclerotic Panniculopathy

United States
Jazz Pharmaceuticals

Completed

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Multiple Sclerosis | Spasticity

Czechia
Jazz Pharmaceuticals

Completed

An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Multiple Sclerosis

United Kingdom
Regeneron Pharmaceuticals

Completed

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Melanoma

United States
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Cornerstone Pharmaceuticals

Completed

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Pancreatic Cancer Metastatic

United States, Korea, Republic of, France, Israel, Germany, Belgium
Jazz Pharmaceuticals

Completed

An Observational Post-Marketing Safety Registry of Sativex®

Multiple Sclerosis | Diabetes | Cancer | Neuropathic Pain
Jazz Pharmaceuticals

Completed

A Study of GWP42006 in People With Focal Seizures - Part B

Epilepsy | Focal Seizures

Italy, Poland, United Kingdom, Spain, Hungary, Czechia
Jazz Pharmaceuticals

Completed

A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Cerebral Palsy

Czechia, Israel, United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Healthy

Belgium
Botanix Pharmaceuticals

Completed

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom

Clinical Trials Sponsored by Transcept Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations